Tumor lysis syndrome (TLS) is a rare serious acute complication of cancer therapy, reported mainly following chemotherapy in patients with large tumor load and chemosensitive disease. These are mainly patients with non-Hodgkin's lymphoma, leukemia and rarely in solid tumors. It is less frequently described after radiotherapy for lymphoid and hematological malignancies. TLS following radiotherapy for solid tumors is a very rare complication. In this report/review we describe a seventy-three-year-old male patient with progressive metastatic carcinoma of the breast to the lungs, liver and bone. He was referred for radiotherapy because of generalized bony pains. The patient was planned for sequential hemi-body irradiation starting with the more symptomatic upper half body. After premedication, he was given 8.5 Gy to the mid point at the maximum chest separation with anterior lung attenuator limiting uncorrected lung dose to 6.15 Gy. A further 3.5 Gy electron boost to the fungating breast tumor was given to the 100%.
The patient
A 73-year-old male patient presented with a two-year history of a painless right breast mass. In the previous months, the swelling ulcerated through the skin with discharge and bleeding. On examination, he was in good general condition, performance status 100%, had an 8 x 3 cm central right breast mass, fixed to the pectoralis major muscle with ulceration of the skin and a separate satellite skin nodule above and lateral to the original mass. Two enlarged glands felt in the right axilla. The rest of clinical examination was unremarkable. The patient was a known diabetic and heavy smoker. A trucut needle biopsy revealed grade 3 infiltrating duct carcinoma. Tc" isotope bone scan showed multiple bone secondries and CT scan of the chest and abdomen demonstrated the breast mass but more axillary nodes than the two nodes felt, mediastinal nodal enlargement, lung and liver secondries.
The patient was started on tamoxifen followed by six courses of cycolphosphamide, Methotrexate and 5-flurouracil (5-FU) (CMF) chemotherapy for disease progression. Six months from presentation, he developed generalized bony pains, more in the ribs, dorsal spine, both shoulders and the neck. Clinically the breast mass was larger, performance status dropped to 30%, and needed increasing doses of morphine to control his pains. He was admitted for sequential hemi-body irradiation starting with the more symptomatic upper half body and electron beam boost to the fungating breast mass.
Pre-treatment blood investigations were essentially normal apart from slightly elevated WBC at 11.1, raised ESR 105 MM/H, and HGB 126 g/1 just below normal, Platelets 204 x 10 9 /l, CA 15-3: 41 U/ml, CEA 2.8 ug/1 renal and liver function tests were within normal limits. However, his liver enzymes were mildly raised with alkaline phosphatase 460 U/l (normal 220-480) and AST of 75 U/l (normal 10-45).
Treatment set up and preparation has been previously described [1] . The patient was given 100 mg of hydrocortisone in 500 mis of normal saline over one hour infusion followed by a i.v. bolus injection of 8 mg Zofran. Immediately after this he was given upper hemi-body radiation (UHBI) with anterior lung attenuator to limit the uncorrected lung dose to 6.15 Gy and the mid point dose to 8.5 Gy to the maximum chest separation. Anterior and posterior fields covering the head and extending down to the anterior superior iliac spine using six MV photons. The breast lesion was under the lung filter and an extra direct 12 MeV electron field covering the fungating breast lesion was added giving a single 3.5 Gy at 100% thus bringing the total applied breast dose to approximately 9.65 Gy.
Twenty-four hours after irradiation the patient felt better, pains were easier. However, exactly 48 hours after irradiation he became drowsy and confused. On examination his vital signs were normal apart from rapid pulse at 100/min. Morphine was discontinued, a blood culture and CT scan of the brain were requested. The results of these were normal, however, a blood screen showed raised potassium, phosphates, urate, urea, creatinine and border line low calcium suggesting acute renal failure (see Table 1 ). We sought nephrology opinion, he was started on i.v. infusion of normal saline at 100 cc/hour with monitoring of fluid input and output. A nasogastric tube was inserted and also started on allopurinol 300 mg twice daily for hyperuricemia and calcium carbonate 600 mg eight hourly for urine alkalnisation. Repeat blood tests were done twice daily AM & PM for the next three days (see Table 1 ). Twenty-four hours later fluid IVI was increased to 150 cc/hour. There was slight improvement of his renal function, hypocalcemia and hyperphosphatemia returned to normal levels within two days (Table 1) . However, his condition continued to deteriorate and IVI was reduced to lOOcc/hour due to reduce urinary output. Five days after irradiation he developed deep coma and was referred to palliative care and died three days later.
Discussion and conclusion
Tumor lysis syndrome a syndrome of hyperkalemia, hyperphosphatemia, hyperuricemia and hypocalcemia, is a rare acute metabolic complication of cancer therapy. It is believed to be due to massive tumor cell death as a result of treatment and release of intracellular contents in the circulation. Cardiac arrhythmia or cardiac arrest a result of hyperkalemia or renal failure as a result of hyperphosphatemia and hyperuricemia is not uncommon sequelae of this complication. TLS is commonly seen in patients with chemosensitive haematological and lymphoid malignancies following the use of cytotoxic drug therapy [2] [3] [4] . It has also been described, but less frequently, in such patients following radiotherapy [5] [6] [7] . TLS following chemotherapy or radiotherapy for solid tumors is very rare [8, 9] .
Spontaneous TLS, following steroid therapy or biological response modifiers has also been described in patients with NHL, leukemia and solid tumors [10] [11] [12] [13] [14] [15] .
It is important to recognize patients at risk before instituting any form of therapy. These would be mainly patients with large tumor load, high growth fraction and known sensitivity to chemotherapy such as hematological and lymphoid malignancies and possibly patients with small-cell lung cancer [8] . The syndrome could be reversed if recognized early [9] . Hydration, forced diuresis, urinary alkalinisation and the prophylactic use of allopurinol is recommended in such patients especially those with border line renal function. More recently urate oxidase the enzyme that converts uric acid to allantoin (ten times more soluble than uric acid) has been used with significant reduction in uric acid, creatinine and urea when compared to allopurinol [16] .
Increasing awareness of oncologists dealing with leukemia and high-grade lymphomas with this syndrome and the routine use of prophylactic measures resulted in significantly less mortality in patients with hematological or lymphoid malignancies when compared to those with solid tumors [17] . Because of the rarity of this syndrome in patients with solid tumors, prophylactic measures are not recommended by some authors [8] .
TLS in patients with breast cancer is a very rare considering the large number of patients receiving neoadjuvant, adjuvant and therapeutic chemotherapy. However, breast cancer is the second commonest solid tumor following small-cell lung cancer in one review [8] . The syndrome has also been described in a patient receiving tamoxifen for breast cancer [18] . Sklarin and Markham described a patient with inflammatory breast carcinoma presenting with spontaneous TLS who relapsed following chemotherapy and subsequently died eight days later [11] . They emphasized the rapid cellular turn over in this type of breast cancer and presumed chemo-sensitivity as a possible cause. However Drakos et al. [17] described another patient with metastatic non inflammatory breast carcinoma who developed TLS following singleagent mitoxantrone chemotherapy. They pointed out some breast cancers can be extremely sensitive to chemotherapy. Some breast tumors are also sensitive to irradiation and this may be the case with the patient reported here. Although pre-treatment results were essentially normal, his potassium and phosphates were at the upper border of normal and perhaps this should have been corrected prior to irradiation, although some authors do not recommend the routine use of prophylactic measures in patient with solid tumors [8] . Hemodialysis has been used in patients with TLS with good results especially those with curable hematological or lymphoid malignancies [19] . Hemodialysis was considered inappropriate for this patient in view of disease progression on tamoxifen and chemotherapy, and the sudden deterioration of his condition despite the early marginal improvement of renal function.
